DiagnoCure Inc. announced earnings results for the second quarter ended April 30, 2013. For the quarter, the company reported total revenues of $164,262 against $1,063,131 a year ago. Net profit (before stock-based compensation, depreciation and amortization) was $609,780 against net profit of $10,881 a year ago.

Net loss and comprehensive loss was $849,344 against $272,216 a year ago. Basic and diluted net loss per share was $0.02 against $0.01 a year ago. Revenues decrease of $898,869 is attributable to the payment made by Gen-Probe in relation to the FDA milestone reached for PROGENSA(R) PCA3 in the second quarter 2012 ($502,600).

The remaining decrease is attributable to the termination, on January 11, 2013 of the development and license agreements signed in June 2011 with Signal Genetics.